GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » Beneish M-Score

American Renal Associates Holdings (American Renal Associates Holdings) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for American Renal Associates Holdings's Beneish M-Score or its related term are showing as below:

During the past 8 years, the highest Beneish M-Score of American Renal Associates Holdings was 0.00. The lowest was 0.00. And the median was 0.00.


American Renal Associates Holdings Beneish M-Score Historical Data

The historical data trend for American Renal Associates Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Renal Associates Holdings Beneish M-Score Chart

American Renal Associates Holdings Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial - -2.72 -3.14 -3.16 -2.63

American Renal Associates Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.63 -2.63 -2.71 -3.33 -3.36

Competitive Comparison of American Renal Associates Holdings's Beneish M-Score

For the Diagnostics & Research subindustry, American Renal Associates Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Renal Associates Holdings's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's Beneish M-Score falls into.



American Renal Associates Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of American Renal Associates Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9361+0.528 * 1.0432+0.404 * 0.9775+0.892 * 0.9877+0.115 * 0.9679
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9078+4.679 * -0.158048-0.327 * 0.9863
=-3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep20) TTM:Last Year (Sep19) TTM:
Total Receivables was $96.1 Mil.
Revenue was 209.689 + 205.148 + 193.182 + 206.079 = $814.1 Mil.
Gross Profit was 59.332 + 58.266 + 38.96 + 51.685 = $208.2 Mil.
Total Current Assets was $263.5 Mil.
Total Assets was $1,160.2 Mil.
Property, Plant and Equipment(Net PPE) was $278.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $39.9 Mil.
Selling, General, & Admin. Expense(SGA) was $105.8 Mil.
Total Current Liabilities was $252.7 Mil.
Long-Term Debt & Capital Lease Obligation was $662.8 Mil.
Net Income was -2.691 + 0.795 + -7.234 + 0.09 = $-9.0 Mil.
Non Operating Income was -0.042 + -0.356 + 1.699 + -1.127 = $0.2 Mil.
Cash Flow from Operations was 19.473 + 137.284 + 13.678 + 3.718 = $174.2 Mil.
Total Receivables was $103.9 Mil.
Revenue was 211.429 + 213.252 + 191.762 + 207.806 = $824.2 Mil.
Gross Profit was 56.841 + 60.236 + 43.581 + 59.281 = $219.9 Mil.
Total Current Assets was $212.4 Mil.
Total Assets was $1,117.9 Mil.
Property, Plant and Equipment(Net PPE) was $295.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $40.9 Mil.
Selling, General, & Admin. Expense(SGA) was $118.0 Mil.
Total Current Liabilities was $213.0 Mil.
Long-Term Debt & Capital Lease Obligation was $681.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(96.093 / 814.098) / (103.93 / 824.249)
=0.118036 / 0.126091
=0.9361

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(219.939 / 824.249) / (208.243 / 814.098)
=0.266836 / 0.255796
=1.0432

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (263.543 + 278) / 1160.201) / (1 - (212.435 + 295.666) / 1117.945)
=0.533233 / 0.545504
=0.9775

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=814.098 / 824.249
=0.9877

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(40.927 / (40.927 + 295.666)) / (39.94 / (39.94 + 278))
=0.121592 / 0.125621
=0.9679

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(105.787 / 814.098) / (117.98 / 824.249)
=0.129944 / 0.143136
=0.9078

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((662.831 + 252.693) / 1160.201) / ((681.459 + 212.981) / 1117.945)
=0.789108 / 0.800075
=0.9863

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.04 - 0.174 - 174.153) / 1160.201
=-0.158048

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

American Renal Associates Holdings has a M-score of -3.26 suggests that the company is unlikely to be a manipulator.


American Renal Associates Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of American Renal Associates Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915
American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.
Executives
Don E Williamson officer: EVP, Chief Operating Officer 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola officer: VP and General Counsel AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci director, officer: Chief Executive Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal director, officer: President C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber director C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar director 1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish director C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer director 9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller director FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher officer: Former VP & CFO 500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers officer: Interim CFO and Interim CAO 500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa officer: VP and General Counsel C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan director 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox officer: VP & Chief Financial Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915

American Renal Associates Holdings (American Renal Associates Holdings) Headlines

From GuruFocus